A study of the relationship between circulating cytokines (interleukin-2 receptor and tumor necrosis factor receptor 2) and risk of B-cell non-hodgkin lymphoma
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05996-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Sara El-Sayed Abd El-Ghani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Clinical Hematology Unit, Kasr Alainy Faculty of Medicine, Cairo University, Kasr Al-Ainy, old Cairo, Cairo, Egypt. sar…. Hauptthemen laut MEDLINE: Receptors, Interleukin-2, Lymphoma, B-Cell, Receptors, Tumor Necrosis Factor, Type II. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.
Abstract (Originalsprache)
Mature B-cell non-Hodgkin lymphoma (B-NHL) occurs due to uncontrolled B-lymphocyte clonal expansion. Cytokines can directly stimulate B-cell proliferation and prevent B-cell apoptosis. Dysregulation of cytokines may play an important role in the development of B-NHL by enhancing chromosomal translocation, which is the hallmark of B-NHL. Both interleukin 2 and tumor necrosis factor-α are proinflammatory cytokines and play important roles in the growth, differentiation, and apoptosis of B cells. We conducted a prospective case-control study applied to 50 patients with B-NHL at Kasr Al Aini Hospital, Cairo University, and 50 age- and sex-matched controls. Clinical, laboratory and imaging data were collected. In all patients and controls, sIL-2R and sTNF-R2 levels were measured by enzyme-linked immunosorbent assay (ELISA). The Spearman correlation test was used to evaluate the correlation between the studied cytokines and clinical, laboratory and imaging findings. Sensitivity analysis was conducted to detect the cutoff values of the studied cytokines. Serum levels of sIL-2R and sTNF-R2 were significantly higher in patients than in controls. Additionally, their levels were significantly higher in aggressive types and advanced stages of lymphoma. Also, the studied cytokines were significantly correlated with different clinical and laboratory parameters of lymphoma. The level of sIL-2R and sTNF-R2 were closely related to the type of lymphoma ( P value ˂ 0.001 and 0.012, respectively), further it was also associated with the natural history of lymphoma (aggressive vs. indolent) ( P value ˂0.001 and 0.04 respectively). We concluded that Pretreatment levels of sIL-2R and sTNF-R2 may play a role in the natural history and prognosis of lymphoma. They may be used as a prognostic factor for B-NHL patients and may also help with treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, Clinical Hematology Unit, Kasr Alainy Faculty of Medicine, Cairo University, Kasr Al-Ainy, old Cairo, Cairo, Egypt. sara.elsayed@kasralainy.edu.eg.
- Internal Medicine Department, Clinical Hematology Unit, Kasr Alainy Faculty of Medicine, Cairo University, Kasr Al-Ainy, old Cairo, Cairo, Egypt.
- Department of Clinical and Chemical Pathology, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Förderung
- Cairo University
Zitieren
APA
Abd El-Ghani, S. E., Abido, H. Y., Tawfik, N. M., Shaheen, G., & Ellithy, H. N. (2024). A study of the relationship between circulating cytokines (interleukin-2 receptor and tumor necrosis factor receptor 2) and risk of B-cell non-hodgkin lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-024-05996-2
Vancouver
Abd El-Ghani SE, Abido HY, Tawfik NM, Shaheen G, Ellithy HN. A study of the relationship between circulating cytokines (interleukin-2 receptor and tumor necrosis factor receptor 2) and risk of B-cell non-hodgkin lymphoma. Annals of Hematology. 2024. doi:10.1007/s00277-024-05996-2
BibTeX
@article{AbdElGhani2024,
author = {Abd El-Ghani, Sara El-Sayed and Abido, Heba Youssef and Tawfik, Nehad Mohamed and Shaheen, Gehan and Ellithy, Hend Nabil},
title = {A study of the relationship between circulating cytokines (interleukin-2 receptor and tumor necrosis factor receptor 2) and risk of B-cell non-hodgkin lymphoma},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05996-2}
}
EUVIMED